Parkinson's Disease Market on Track for Major Expansion by 2034, According to DelveInsight | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma, Chase Therapeutics Corporation, Mthera Pharma

DelveInsight's "Parkinson's Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Parkinson's Disease, historical and forecasted epidemiology as well as the Parkinson's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Parkinson's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson's Disease Market Forecast
https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Parkinson's Disease Market Report:
• The Parkinson's Disease market size was valued approximately USD 3,385 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In July 2024, The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL), a once-monthly injection for intravenous infusion by Eli Lilly and Company (NYSE: LLY). This treatment is aimed at adults with early symptomatic Alzheimer's disease (AD), including those with mild cognitive impairment (MCI) and mild dementia, who have confirmed amyloid pathology. Kisunla is the first and only therapy targeting amyloid plaques with evidence supporting the discontinuation of treatment once these plaques are removed, potentially leading to reduced treatment costs and fewer infusions.
• In 2023, the market size for Parkinson's disease in the US was around USD 2,169.9 million. This is expected to grow, driven by increasing disease awareness and the introduction of emerging therapies.
• In 2023, the total market size for the EU4 and the UK was estimated at approximately USD 916.8 million, accounting for nearly 27% of the overall market revenue for the 7MM.
• In 2023, Germany had the largest market share among the EU4 and the UK, totaling around USD 347 million, followed by France at approximately USD 205.7 million, and the UK at USD 125.8 million.
• In 2023, Japan's total market size for Parkinson's disease was approximately USD 299 million, and this figure is expected to grow during the forecast period.
• DelveInsight's epidemiology model estimated that there were around 2.6 million diagnosed prevalent cases of Parkinson's disease across the 7MM in 2023. This number is expected to rise over the forecast period (2024-2034) due to growing awareness, an aging population, and improvements in diagnostic methods.
• In 2023, the US had the highest number of diagnosed prevalent cases of Parkinson's disease within the 7MM, totaling approximately 1.2 million.
• In 2023, Germany had the highest number of diagnosed prevalent cases of Parkinson's disease among the EU4 and the UK, with nearly 460,000 cases, followed by France with approximately 272,000 cases. In contrast, Italy had the fewest, with around 154,000 cases.
• Japan had around 206,000 diagnosed prevalent cases of Parkinson's disease in 2023, with this number expected to rise over the forecast period.
• In 2023, the stage-specific diagnosed prevalent cases of Parkinson's disease in the EU4 and the UK were approximately 156,000 for Stage I, 395,000 for Stage II, 392,000 for Stage III, 212,000 for Stage IV, and 52,000 for Stage V.
• Key Parkinson's Disease Companies: Amneal Pharmaceuticals, AbbVie, Newron Pharmaceuticals, Zambon, Eisai, Kyowa Kirin, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharmaceutical, Pharma Two B, Jazz Pharmaceuticals, Chase Therapeutics Corporation, Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, BrainX Corporation, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Bial - Portela C S.A., Neuraly, Inc., Forest Hills Lab, Intra-Cellular Therapies, Inc., FAScinate Therapeutics Inc., AC Immune SA, and others
• Key Parkinson's Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), XADAGO/EQUFINA (safinamide), NOURIANZ/NOURIAST (istradefylline), SPN-830 (apomorphine infusion device), ABBV-951, ND0612, CVN-424, IPX203, P2B001, Suvecaltamide (JZP385), CTC-413, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, Ceftriaxone, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, Tavapadon, IkT-148009, Opicapone, NLY01, Gemfibrozil, Lenrispodun, KM-819, ACI-7104.056, and others
• The Parkinson's Disease epidemiology based on gender analyzed that there is male preponderance in the Parkinson's disease cases in the 7MM
• The Parkinson's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson's Disease pipeline products will significantly revolutionize the Parkinson's Disease market dynamics.

Parkinson's Disease Overview
Parkinson's disease (PD) is a progressive neurological disorder that affects movement. It occurs when nerve cells in the brain, specifically in an area called the substantia nigra, become damaged or die. These nerve cells produce dopamine, a neurotransmitter that is crucial for controlling movement and coordination. The loss of dopamine leads to the symptoms associated with Parkinson's disease.

Get a Free sample for the Parkinson's Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Parkinson's Disease Epidemiology Segmentation:
The Parkinson's Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Parkinson's Disease
• Prevalent Cases of Parkinson's Disease by severity
• Gender-specific Prevalence of Parkinson's Disease
• Diagnosed Cases of Episodic and Chronic Parkinson's Disease

Download the report to understand which factors are driving Parkinson's Disease epidemiology trends @ Parkinson's Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson's Disease market or expected to get launched during the study period. The analysis covers Parkinson's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Parkinson's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Parkinson's Disease Therapies and Key Companies
• CREXONT (carbidopa and levodopa) ER capsules: Amneal Pharmaceuticals
• PRODUODOPA (foslevodopa/foscarbidopa): AbbVie
• XADAGO/EQUFINA (safinamide): Newron Pharmaceuticals/Zambon/Supernus Pharmaceuticals/Eisai
• NOURIANZ/NOURIAST (istradefylline): Kyowa Kirin
• SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/Britannia Pharmaceuticals
• ABBV-951: AbbVie
• ND0612: Mitsubishi Tanabe Pharma(NeuroDerm)
• CVN-424: Cerevance
• IPX203: Amneal Pharmaceutical
• P2B001: Pharma Two B
• Suvecaltamide (JZP385): Jazz Pharmaceuticals
• CTC-413: Chase Therapeutics Corporation
• MT101-5: Mthera Pharma Co., Ltd.
• BIA 28-6156: Bial R&D Investments, S.A.
• RO7046015: Hoffmann-La Roche
• ND0612: NeuroDerm Ltd.
• pimavanserin tartrate: Tasly Pharmaceutical
• Ceftriaxone: BrainX Corporation
• UCB0599: UCB Biopharma SRL
• Tocovid Suprabio (HOV-12020): National Neuroscience Institute
• Altropane (123I) Injection: GE Healthcare
• Tavapadon: Cerevel Therapeutics, LLC
• IkT-148009: Inhibikase Therapeutics, Inc.
• Opicapone: Bial - Portela C S.A.
• NLY01: Neuraly, Inc.
• Gemfibrozil: Forest Hills Lab
• Lenrispodun: Intra-Cellular Therapies, Inc.
• KM-819: FAScinate Therapeutics Inc.
• ACI-7104.056: AC Immune SA

Discover more about therapies set to grab major Parkinson's Disease market share @ Parkinson's Disease Treatment Landscape
https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Market Drivers
• Growing research and development are increasing the demand for better diagnosis and treatment options for Parkinson's Disease.
• In recent years, drugs with a novel mechanism of action and combinations are being investigated to overcome the challenges of this entity

Parkinson's Disease Market Barriers
• The development of a disease-modifying drug can potentially increase the Parkinson's Disease market share potential.
• In advanced countries, there is a huge annual psychological, social, and economic burden (QALY) due to Parkinson's Disease.

Scope of the Parkinson's Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Parkinson's Disease Companies: Amneal Pharmaceuticals, AbbVie, Newron Pharmaceuticals, Zambon, Eisai, Kyowa Kirin, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharmaceutical, Pharma Two B, Jazz Pharmaceuticals, Chase Therapeutics Corporation, Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, BrainX Corporation, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Bial - Portela C S.A., Neuraly, Inc., Forest Hills Lab, Intra-Cellular Therapies, Inc., FAScinate Therapeutics Inc., AC Immune SA, and others
• Key Parkinson's Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), XADAGO/EQUFINA (safinamide), NOURIANZ/NOURIAST (istradefylline), SPN-830 (apomorphine infusion device), ABBV-951, ND0612, CVN-424, IPX203, P2B001, Suvecaltamide (JZP385), CTC-413, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, Ceftriaxone, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, Tavapadon, IkT-148009, Opicapone, NLY01, Gemfibrozil, Lenrispodun, KM-819, ACI-7104.056, and others
• Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies
• Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Parkinson's Disease Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Market Access and Reimbursement

To know more about Parkinson's Disease companies working in the treatment market, visit @ Parkinson's Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Parkinson's Disease Market Report Introduction
2. Executive Summary for Parkinson's Disease
3. SWOT analysis of Parkinson's Disease
4. Parkinson's Disease Patient Share (%) Overview at a Glance
5. Parkinson's Disease Market Overview at a Glance
6. Parkinson's Disease Disease Background and Overview
7. Parkinson's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Parkinson's Disease
9. Parkinson's Disease Current Treatment and Medical Practices
10. Parkinson's Disease Unmet Needs
11. Parkinson's Disease Emerging Therapies
12. Parkinson's Disease Market Outlook
13. Country-Wise Parkinson's Disease Market Analysis (2020-2034)
14. Parkinson's Disease Market Access and Reimbursement of Therapies
15. Parkinson's Disease Market Drivers
16. Parkinson's Disease Market Barriers
17. Parkinson's Disease Appendix
18. Parkinson's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Parkinson's Disease Epidemiology https://www.delveinsight.com/report-store/parkinsons-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Parkinson's Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Parkinson's Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Retinoblastoma Market
https://www.delveinsight.com/report-store/retinoblastoma-market
DelveInsight's "Retinoblastoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Retinoblastoma, historical and forecasted epidemiology as well as the Retinoblastoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Sickle Cell Disease Market
https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market
DelveInsight's "Skin Burns Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom).

Skin Burns Market
https://www.delveinsight.com/report-store/skin-burns-market
DelveInsight's "Skin Burns Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Thymus Cancer Market
https://www.delveinsight.com/report-store/thymus-cancer-market
DelveInsight's "Thymus Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Thymus Cancer, historical and forecasted epidemiology as well as the Thymus Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.